- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
Cobimetinib Plus Atezolizumab Active in Microsatellite Stable mCRC
June 29th 2016, 11:50pm
ESMO Gastrointestinal Cancers Congress
Combined inhibition of the PD-L1/PD-1 axis with atezolizumab (Tecentriq) and the MEK pathway with cobimetinib (Cotellic) showed promising clinical activity and a good safety profile in heavily pretreated patients with microsatellite stable metastatic colorectal cancer.
Second-Line Regorafenib Boosts Survival in HCC
June 28th 2016, 8:02pm
ESMO Gastrointestinal Cancers Congress
Second-line treatment with regorafenib (Stivarga) improved overall survival by 2.8 months compared with placebo for patients with unresectable hepatocellular carcinoma who progressed on sorafenib (Nexavar).
Inotuzumab Ozogamicin Improves Outcomes in Relapsed/Refractory ALL
June 13th 2016, 1:18am
European Hematology Association Congress
Inotuzumab ozogamicin demonstrated significantly improved progression-free survival and complete remission rates compared with chemotherapy for patients with relapsed or refractory acute lymphoblastic leukemia.
Long-Term COMFORT-I Data Confirm Ruxolitinib Survival Benefit
June 12th 2016, 11:58pm
European Hematology Association Congress
Final 5-year efficacy and safety data from the phase III COMFORT-I trial confirm previous findings that ruxolitinib confers a significant benefit in patients with intermediate-2 and high-risk myelofibrosis.
Antibodies From Cured AML Patients Kill Leukemia Cells
June 12th 2016, 9:45pm
European Hematology Association Congress
Patients with acute myeloid leukemia who are cured after allogeneic hematopoietic stem cell transplantation produce antibodies that destroy leukemia cells.
Daratumumab Triplet Reduces Risk of Progression by 63% in Myeloma
June 12th 2016, 12:54am
European Hematology Association Congress
Combining the CD38-targeted antibody daratumumab with lenalidomide and dexamethasone reduced the risk of disease progression by 63% versus lenalidomide and dexamethasone alone in patients with relapsed/refractory multiple myeloma, according to findings from the phase III POLLUX (MMY3003) trial.
Targeted Therapies Could Revolutionize AML Treatment
June 12th 2016, 12:45am
European Hematology Association Congress
A host of novel agents that target distinct molecular targets are pushing complete remission rates beyond historical boundaries for patients with acute myeloid leukemia.
Vadastuximab Talirine, HMA Combo Induces Impressive Remissions in AML
June 12th 2016, 12:10am
European Hematology Association Congress
Frontline treatment with the CD33-directed antibody-drug conjugate vadastuximab talirine plus a hypomethylating agent induced deep and durable remissions for older patients with acute myeloid leukemia.
Dr. Christian Gisselbrecht on Defining Refractory Disease in DLBCL
June 11th 2016, 10:29pm
European Hematology Association Congress
Christian Gisselbrecht, MD, a Professor of Haematology in the Haemato-Oncology Department of Hôpital Saint-Louis, at Diderot University, Paris, discusses stratifying refractory disease in aggressive diffuse large b-cell lymphoma (DLBCL).
Dr. Wojciech Jurczak on MOR208 in Non-Hodgkin's Lymphoma
June 11th 2016, 2:43pm
European Hematology Association Congress
Wojciech Jurczak, MD Head of Lymphoma, Department of Hematology, Jagiellonian University, Kopernika, Poland, discuses a subgroup analyses of diffuse large b-cell lymphoma (DLBCL) and indolent lymphoma cohorts from a phase IIa study of single-agent MOR208 in patients with relapsed or refractory non-Hodgkin's lymphoma (NHL).
Stopping TKIs Proven Safe in Chronic Phase CML
June 11th 2016, 3:24am
European Hematology Association Congress
Tyrosine kinase inhibitors can safely be halted in select patients with chronic phase chronic myeloid leukemia followed a maintained deep molecular remission.
Blinatumomab Nearly Doubles Survival in Acute Lymphoblastic Leukemia
June 11th 2016, 2:55am
European Hematology Association Congress
The median overall survival with the anti-CD19 immunotherapy blinatumomab was 7.7 months versus 4 months with standard chemotherapy in patients with Philadelphia chromosome–negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia, according to results from the phase III TOWER study.
Ibrutinib Highly Effective for Del17p CLL in Combined Analysis
June 11th 2016, 2:32am
European Hematology Association Congress
Ibrutinib continued to demonstrate impressive antitumor activity in a pooled analysis of 243 patients with deletion 17p chronic lymphocytic leukemia.
Dr. Ruben Mesa on COMFORT-I for Myelofibrosis
June 10th 2016, 11:46pm
Cabozantinib Improves Survival in Renal Cell Carcinoma
June 9th 2016, 1:01am
Cabozantinib reduced the risk of death by 34% compared with everolimus in patients with previously treated advanced renal cell carcinoma, according to updated data from the phase III METEOR trial.
Dr. Edward Kim on ASCO's TAPUR Trial
June 9th 2016, 12:33am
Edward S. Kim, MD, chair, Solid Tumor Oncology and Investigational Therapeutics, Donald S. Kim Distinguished Chair for Cancer Research, Levine Cancer Institute, Carolinas HealthCare System, discusses the significance of the TAPUR clinical trial, which is being conducted by ASCO.
CAR Therapy Achieves Durable Responses in Refractory Lymphoma
June 8th 2016, 4:16am
Three-fourths of patients with advanced lymphoma achieved durable objective responses to treatment with chimeric antigen receptor T-cell therapy targeting CD19 even after a low-dose chemotherapy conditioning regimen.